CN105695619A - Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application - Google Patents
Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application Download PDFInfo
- Publication number
- CN105695619A CN105695619A CN201610270438.0A CN201610270438A CN105695619A CN 105695619 A CN105695619 A CN 105695619A CN 201610270438 A CN201610270438 A CN 201610270438A CN 105695619 A CN105695619 A CN 105695619A
- Authority
- CN
- China
- Prior art keywords
- gene
- detection
- seq
- type
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
The invention discloses a casein kinase-1 (CK1) gene mutation detection reagent based on peptide nucleic acid probes, a PCR detection method and application and belongs to the technical field of basic biological research and biological detection.The detection reagent comprises primers, the peptide nucleic acid fluorescent probes and wild type complementary peptide nucleic acid sequences.The sequences of the forward primers are shown in SEQ ID NO.1 and NO.3 in a sequence table, and the sequences of the reverse primers are shown in SEQ ID NO.2 and NO.4 in the sequence table.The sequences of the peptide nucleic acid probes are shown in SEQ ID NO.5 and NO.6 in the sequence table.The wild type complementary peptide nucleic acid sequences are shown in SEQ ID NO.7 and NO.8 in the sequence table.The CK1 gene mutation condition in a Wnt signal channel can be rapidly found from the transcriptional level, the remarkable advantages of being high in specificity and sensitivity and the like are achieved, and tools are provided for screening of anti-cancer drugs, discussion on new target drugs and basic scientific research.
Description
Technical field
The present invention relates to molecular biology and clinical molecular diagnosis technical field, particularly relate to a kind of based on casein kinase-1 (CK1) the detection in Gene Mutation reagent of peptide nucleic acid probe, PCR detection method and application。
Background technology
Wnt signal path is widely present in invertebrates and vertebrates, is a class at the conservative signal path of spore process camber。Wnt signal, in the early development of animal embryo, orga-nogenesis, tissue regeneration and other physiological process, has vital effect。If the key protein in this signal paths is undergone mutation or unconventionality expression, cause that abnormal signal activates, it is possible to the generation of induced cancer。Wnt signal path includes the Wnt signal path of classics and non-classical Wnt signal path, in classical path and Wnt-β-catenin signal path, the Wnt factor is by suppressing phosphorylation and the degraded of endocellular liberation β-catenin albumen after the Frizzle/LRP5/6 cooperative expert systems on active cell film, the core displacement of β-catenin albumen will be there is in the β-catenin protein level in Cytoplasm after raising, cause that in nucleus, β-catenin albumen raises, in karyon, β-catenin albumen can combine Pygo2, Bcl-9 and FoxM1 albumen jointly forms complex with TCF/LEF-1 transcription factor family and activates the transcriptional activation of Wnt signal path downstream target gene。
CK1 albumen is one of β-catenin upstream important member in Wnt signal path。Its Main Function is able to form complex with the protein binding such as Axin2, GSK3 β, APC, promotes the degraded of β-catenin in Cytoplasm。Increasing research at present has been found that CK1 albumen all presents sudden change in various degree in a lot of tumors。
Study the core element regulatory mechanism of core signal path at present, and the expression that some important member is in cell, have become as a kind of key means for the treatment of tumor, Wnt signal path research in cancer in recent years, and CK1 albumen is as the research of its sudden change level of Wnt signal path important member, have become as the major issue that research and development tumour medicine is badly in need of solving, particularly in the sudden change occurred in CK1 gene kinase domain, CK1 protein exhibits function is played very important effect, such as in Testicular Germ Cell cancerous cell, detect that G72DS suddenlys change, hepatoma carcinoma cell detects F101L sudden change etc.。
Peptide nucleic acid(PNA) (peptidenucleicacids, PNA) is that a class replaces the DNA analog of sugar phosphate backbone with polypeptide backbone。It is the first generation, second filial generation antisense agent basis on, the third generation antisense agent of also final synthetic is built by Computer Design, it it is a kind of brand-new DNA analog, namely instead of the pentose phosphate diester linkage skeleton in DNA with neutral peptide chain amide 2-aminoethylglycine key, remaining is identical with DNA, PNA can pass through the form identification of Watson-Crick base pairing and in conjunction with DNA or RNA sequence, forms stable double-spiral structure。Owing to PNA is not electronegative, and between DNA and RNA, it is absent from electrostatic repulsion, thus the stability combined and specificity all greatly improve；It is different from the hybridization between DNA or DNA, RNA, the hybridization of PNA and DNA or RNA is little affected by the impact of hybridization system salinity, be much better than DNA/DNA or DNA/RNA with the hybridization ability of DNA or RNA molecule, show significantly high hybridization stability, excellent distinguished sequence identification ability, not by nuclease and protease hydrolysis。
This method adopts the PNA oligomer of distinguished sequence as probe。It it is the analog of the nucleic acid of a kind of synthetic due to PNA, and it is achirality, uncharged molecule, avoid oligonucleotide and its target gene in conjunction with time because of mutually exclusive the caused hybridization unstability of electric charge, in conjunction with the impact being susceptible to hybridization solution ionic strength, thus demonstrating extremely strong heterosis, hybrid vigor, substantially increase detection sensitivity。
Summary of the invention
It is an object of the invention to for the signaling molecule CK1 gene mutation situation how determining core in Wnt signal path in prior art, and how to explain the difficulty that core element CK1 sudden change level in tumor cell changes, it is provided that CK1 detection in Gene Mutation reagent, PCR detection method and application in a kind of detection Wnt signal path。
It is an object of the invention to provide a kind of reagent for casein kinase-1 (CK1) detection in Gene Mutation, including the wild type PNA sequence for blocking wild type CK1 gene amplification, for one group of primer pair of specific amplification G72D, F101L saltant type CK1 gene order and saltant type PNA fluorescent probe:
Described detection CK1 gene G72D mutant forward primer such as SEQ ID NO.1；
Described detection CK1 gene G72D sudden change reverse primer such as SEQ ID NO.2；
Described detection CK1 gene F101L mutant forward primer such as SEQ ID NO.3；
Described detection CK1 gene F101L sudden change reverse primer such as SEQ ID NO.4；
Described detection CK1 gene G72D sudden change PNA fluorescent probe such as SEQ ID NO.5；
Described detection CK1 gene F101L sudden change PNA fluorescent probe such as SEQ ID NO.6；
Described specific binding comprise CK1 gene 72 codon wild type PNA sequence such as SEQ ID NO.7。
Described specific binding comprise CK1 gene 101 codon wild type PNA sequence such as SEQ ID NO.8。
The described fluorescent reporter group modifying described 5' end is: FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, and the quenching group modifying described 3' end is: TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL。
Detectable of the present invention also includes PCR reactant liquor, 72 codons and 101 codon mutation type reference materials, 72 codons and 101 codon reference wild-type product, and wherein PCR reactant liquor includes: DEPC water, have exo-acting for 5' → 3' archaeal dna polymerase, dNTPs, 10 × PCRBuffer, RNASIN, M-MLV reverse transcriptase, oligo (dT) and the solution containing Mg ion。
Described 72 codon mutation type reference materials are the recombinant plasmid dna containing SEQNO.9；
Described 72 codon reference wild-type product are the recombinant plasmid dna containing SEQNO.10；
Described 101 codon mutation type reference materials are the recombinant plasmid dna containing SEQNO.11；
Described 101 codon reference wild-type product are the recombinant plasmid dna containing SEQNO.12；
Archaeal dna polymerase exo-acting for the described 5' of having → 3' is Taq enzyme；
Final concentration of in pcr amplification reaction system of the described each component of PCR reactant liquor: Taq enzyme 0.01U/ μ l～0.05U/ μ l, dNTPs0.2～0.6mM, 10 × PCRBuffer1 ×, RNASIN40U/ μ l～60U/ μ l, M-MLV reverse transcriptase 200U/ μ l～320U/ μ l, MgCl21.5～5.0mM, solvent is DEPC water。
Specifically, final concentration of 0.05～0.9 μM of described forward primer, final concentration of 0.05～0.9 μM of described reverse primer, final concentration of 0.05～0.9 μM of described oligo (dT), described complementary final concentration of 0.05～0.9 μM of PNA sequence, final concentration of 0.05～0.9 μM of described fluorescent probe。
Reagent of the present invention carries out the response procedures of real-time fluorescence quantitative PCR: 42 DEG C of reverse transcription 20min；94 DEG C of denaturations, 2min；95 DEG C of degeneration, 30s, 58 DEG C, 45s (collection fluorescence), carry out 40 circulations。
Principles of the invention is by building the one section peptide nucleic acid(PNA) PNA sequence complementary with CK1 gene wild type, when peptide nucleic acid(PNA) PNA sequence and CK1 gene complementation in conjunction with time, arbitrary sudden change all may result in PNA/DNA generation mispairing, so that solution temperature changes。And then carry out fluorescent quantitative PCR according to the CK1 genic mutation type specific peptide nucleic acid(PNA) PNA probe of design and primer pair CK1 mutated genes, after the pcr amplification that takes turns, CK1 genic mutation type and wild type can be made a distinction and come。
Further, present invention also offers the application in the detectable of preparation detection cancerous cell of the described reagent, described cancerous cell is Testicular Germ Cell cancer, hepatocarcinoma。
Compared with prior art, advantages of the present invention and have the benefit effect that CK1 gene is the gene that in Wnt signal path, β-catenin albumen upstream plays critical function, the invention provides and directly detect the reagent of CK1 detection in Gene Mutation in Wnt signal path, quantitative real-time PCR can be passed through by means of described detectable and quickly detect the sudden change of CK1 gene at transcriptional level, and with common real-time fluorescence quantitative PCR the difference is that, the present invention designs wild type PNA sequence, wild type gene group can be effectively suppressed to expand, only enrichment mutated genes amplification, substantially increase detection specificity, the peptide nucleic acid(PNA) PNA fluorescent probe that we use is sensitiveer, the present invention is the screening of cancer therapy drug, the Mechanism Study of new targeted drug both provides very strong instrument。
The experimental system of the present invention can carry out on any real-time fluorescence quantitative PCR instrument simultaneously, above-mentioned primer is placed in eight unions, carry out real-time fluorescence quantitative PCR detection, experimental implementation is simple, low cost, result repeatability, sensitivity is good, is a kind of important means of the research tumor related drugs mechanism of action and basic scientific research。
Accompanying drawing explanation
Fig. 1 is peptide nucleic acid(PNA) mass spectrum described in the embodiment of the present invention；
Fig. 2 is sample, G72D saltant type and reference wild-type product pcr amplification figure；
Fig. 3 is sample, F101L saltant type and reference wild-type product pcr amplification figure；
Detailed description of the invention
By described further below in conjunction with accompanying drawing it will be further appreciated that the features and advantages of the invention。The embodiment provided is only the explanation to the inventive method, and does not limit the present invention in any way all the other contents of announcement。
The present invention is illustrated by hepatoma carcinoma cell, but the present invention is not limited to hepatoma carcinoma cell, and detectable of the present invention can also be applied to Testicular Germ Cell cancer。
All with reference to " molecular cloning: LABORATORY MANUAL ", (gold winter wild goose etc. are translated in relevant DNA and RNA basic operation in embodiment, Science Press, Beijing (1998)) and " fine works Molecular Biology " (Yan Ziyi, Science Press, Beijing (1998))。
HepG2 (HepG2 cells) purchased from American ATCC in the present invention, cultivating the RPMI-1640 culture medium that uses of cell and 10% hyclone all purchased from handsome company, other reagent are mainly purchased from precious biological engineering (Dalian) company limited。
[embodiment 1] primed probe designs
According to American National Biotechnology Information center (NationalCenterforBiotechnologyInformation, NCBI) the CK1mRNA sequence (NCBIReferenceSequence:NM_001025105.2) that (http://www.ncbi.nlm.nih.gov) reports, uses the special CK1 primer of PrimerExpressSoftwareforReal-TimePCR software design and the probe of the exploitation of AppliedBiosystems company。
CK1G72D:
CK1-F:5'-CCAGTTGCTGTACGAGAGCAAG-3'；(SEQNO.1)
CK1-R:5'-GCACATATTCAATTCTACTGATCATCTG-3'；(SEQNO.2)
Saltant type CK1 (PNA)-P:5'FAM-GGGTTGACATCCC-BHQ3'；(SEQNO.5)
Wild type CK1-PNA:5'-GGGTTGGCATCCC-3'(SEQNO.7)
Saltant type target sequence:
GCAGTGAAGCTAGAATCTCAGAAGGCCAGGCATCCCCAGTTGCTGTACGAGAGCAA GCTCTATAAGATTCTTCAAGGTGGGGTTGACATCCCCCACATACGGTGGTATGGTC AGGAAAAAGACTACAATGTACTAGTCATGGATCTTCTGGGACCTAGCCTCGAAGAC CTCTTCAATTTCTGTTCAAGAAGGTTCACAATGAAAACTGTACTTATGTTAGCTGA CCAGATGATCAGTAGAATTGAATATGTGCATACAAAGAATTTTATACACAGAGACA TTAAACCAGATAACTT；(SEQNO.9)
Wild-type target sequence:
GCCAGGCATCCCCAGTTGCTGTACGAGAGCAAGCTCTATAAGATTCTTCAAGGTGG GGTTGGCATCCCCCACATACGGTGGTATGGTCAGGAAAAAGACTACAATGTACTAG TCATGGATCTTCTGGGACCTAGCCTCGAAGACCTCTTCAATTTCTGTTCAAGAAGG TTCACAATGAAAACTGTACTTATGTTAGCTGACCAGATGATCAGTAGAATTGAATA TGTGCATACAAAGAATTT；(SEQNO.10)
CK1F101L:
CK1-F:5'-CCAGTTGCTGTACGAGAGCAAG-3'；(SEQNO.3)
CK1-R:5'-GCACATATTCAATTCTACTGATCATCTG-3'；(SEQNO.4)
Saltant type CK1 (PNA)-P:5'FAM-CGAAGACCTCTTGAATTT-BHQ3'；(SEQNO.6)
Wild type CK1-PNA:CGAAGACCTCTTCAATTT；(SEQNO.8)
Saltant type target sequence:
GCAGTGAAGCTAGAATCTCAGAAGGCCAGGCATCCCCAGTTGCTGTACGAGAGCAA GCTCTATAAGATTCTTCAAGGTGGGGTTGGCATCCCCCACATACGGTGGTATGGTC AGGAAAAAGACTACAATGTACTAGTCATGGATCTTCTGGGACCTAGCCTCGAAGAC CTCTTGAATTTCTGTTCAAGAAGGTTCACAATGAAAACTGTACTTATGTTAGCTGA CCAGATGATCAGTAGAATTGAATATGTGCATACAAAGAATTTTATACACAGAGACA TTAAACCAGATAACTT；(SEQNO.11)
Wild-type target sequence:
GCCAGGCATCCCCAGTTGCTGTACGAGAGCAAGCTCTATAAGATTCTTCAAGGTGG GGTTGGCATCCCCCACATACGGTGGTATGGTCAGGAAAAAGACTACAATGTACTAG TCATGGATCTTCTGGGACCTAGCCTCGAAGACCTCTTCAATTTCTGTTCAAGAAGG TTCACAATGAAAACTGTACTTATGTTAGCTGACCAGATGATCAGTAGAATTGAATA TGTGCATACAAAGAATTT；(SEQNO.12)
Above: F:forward, forward；CK1-F represents the forward primer for detecting nucleic acid。
R:reverse, reversely；CK1-R represents the reverse primer for detecting nucleic acid。
P:probe, fluorescent probe；CK1-P represents the fluorescent probe for detecting nucleic acid, and this fluorescent probe is TaqMan fluorescent probe。
In embodiments of the present invention, the fluorescent reporter group of the 5' end modifying fluorescent probe can be: FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5；The quenching group of the 3' end modifying fluorescent probe can be: TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL, this fluorescent reporter group and quenching group do not affect the amplification of quantitative fluorescent PCR, only the model of instrument used need to be selected to arrange detectable fluorescence signal scope according to the fluorescent reporter group of probe and quenching group。The embodiment of the present invention provide fluorescent probe fluorescent reporter group: FAM, HEX, TET and FAM excitation wavelength be 470-650nm, reception wavelength is 500-700nm；Quenching group: Eclipse, TAMRA, BHQ1。Way of purification after primer synthesis can be: HAP, PAGE and HPLC way of purification。
[embodiment 2] builds the recombiant plasmid containing CK1 genic mutation type and the DNA fragmentation of wild type
One, HepG2 cells is cultivated and goes down to posterity
1) cell is cultivated
All cells system uses RPMI-1640 culture medium (Invitrogen, Carlsbad, CA), and 10% hyclone (Invitrogen, Carlsbad, CA), in 37 DEG C, 5%CO2Cultivate under environment。
2) passage
First by sterilizing suction pipe by the culture fluid sucking-off in Tissue Culture Dish, add PBS to clean 2 times, appropriate trypsin is slowly dripped in cell, treat cell rounding, adjusting angle cell can the add 3ml DMEM culture medium containing 10% hyclone after moving, after repeatedly blowing and beating gently, basis of microscopic observation cellular morphology also counts, according to, in the content of the cell culture dish by appropriate passage to other sterilizings in culture dish, putting into 5%CO after adding the DMEM culture medium of 5ml2Incubator。
Cell counting formula (individual/ml): (4 big lattice total cellular score) × 104× extension rate/4
Two, the extraction of total serum IgE
1) outwell culture medium, after PBS, directly 1mlTrizol is injected culture bottle (wherein cell 5 × 106Individual/ml), suction is uniformly repeatedly；
2) adding the chloroform (for Trizol cumulative volume 1/5) of 0.2ml in equipped with the centrifuge tube of lysate, vibration is mixed 30 seconds, left at room temperature 5 minutes；
3) 12000rpm4 DEG C centrifugal 15 minutes, dividing is three layers mutually。Upper strata: RNA (is about the 60% of Trizol)；Middle: DNA；Lower floor: protein (phenol-chloroform)；
4) careful Aspirate supernatant, transfers in another EP pipe。The supernatant volume that 1ml lysate produces is about 0.4～0.6ml。DNA and protein are contained in organic facies and intermediate layer, avoid touching；
5) supernatant adds the isopropanol of about 0.5ml, and vibration is mixed 30 seconds。Left at room temperature 10 minutes；
6) 12000rpm4 DEG C centrifugal 10 minutes；
7) side at the centrifugal end is formed by RNA precipitate。Careful suction abandons supernatant, notes avoiding suction to abandon RNA precipitate；
8) centrifuge tube adds 75% ethanol (1mlTrizol is 1ml ethanol purge DNA at least) of 1ml pre-cooling, and vibration is mixed 30 seconds, makes precipitation vibrate, centrifugal 1～2 minute of room temperature 12000rpm。Inhale as far as possible and abandon supernatant, prevent RNA precipitate from losing。Repeat above cleaning step once。In 75% ethanol, RNA at least preserves 1 week at 4 DEG C, and-20 DEG C at least preserve 1 year；
9) room temperature selecting liquidity is little, is inverted centrifuge tube on filter paper, dry RNA, but can not be completely dried (5～10 minutes)。With DEPC water 15 μ l dissolution precipitation, hatch 10～15 minutes for 55-60 DEG C。
10) RNA purity detecting
Drip 2 μ lRNA solution in ultramicrospectrophotometer (model: P330-311), and read OD260/OD280 ratio in instrument。
Three, construction recombination plasmid
1) DNA fragmentation containing CK1 genic mutation type and wild type is carried out pcr amplification；
2) PCR primer is carried out double digestion；
Carrier and PCR primer carry out double digestion (reaction system is 30 μ l, 37 DEG C, enzyme action 2 hours) by condition once respectively；
3) (being operated according to test kit description) is reclaimed in rubber tapping after double digestion product electrophoresis；
4) digestion products and plasmid vector are attached；
Above-mentioned double digestion product is through purification (wherein the rubber tapping of carrier digestion products is reclaimed, and after PCR fragment enzyme action, purification step is identical with above-mentioned PCR primer purification step), and under T4DNA ligase effect, 16 DEG C connect overnight。Linked system is as follows: carrier, 2 μ l；PCR fragment, 6 μ l；10xT4buffer, 1 μ l；T4DNAligase, 1 μ l。
5) E. coli competent is converted；
Take above-mentioned connection liquid 5 μ l and be transformed in previously prepared DH5 α Competent cell, ice bath 30 minutes, 42 DEG C of heat shock 2min, put 5min on ice, adding 37 DEG C of shaking table 45min of 1mlLB culture fluid, centrifugal 5000rpm, 1-5min are (centrifugal too not of a specified duration, in order to avoid too real), finally it is uniformly coated on containing on the antibiotic LB flat board of 100ng/ml (100-150 μ l)。Flat board is inverted overnight incubation at 37 DEG C。Picking positive colony bacterium colony turns to draw and contains on the antibiotic LB flat board of 100ng/ml to another block, and it is numbered, is inverted overnight incubation for 37 DEG C。
6) QIAGEN test kit extracting plasmid (carrying out to specifications), makes reference material。
[embodiment 3] quantitative real-time PCR amplified sample
Take the total serum IgE 1-5 μ g of extraction, adding PCR reactant liquor, PCR reactant liquor includes: sterilized water, have exo-acting for 5' → 3' archaeal dna polymerase, dNTPs, 10 × PCRBuffer, RNASIN, M-MLV reverse transcriptase, oligo (dT) and the solution containing Mg ion。Wherein, concentration be 5U/ μ l there is archaeal dna polymerase 0.3 μ l exo-acting for 5' → 3', concentration is the dNTPs2 μ l of 10mmol/L, 10 × PCRBuffer5 μ l, concentration is the RNASIN0.6 μ l of 40U/ μ l, concentration is the M-MLV reverse transcriptase 0.6 μ l of 200U/ μ l, and concentration is the MgCl of 25mmol/L2Solution 5 μ l, adding sterilized water to volume is 50 μ l。Wherein, having archaeal dna polymerase exo-acting for 5' → 3' can be Taq enzyme。
Pcr amplification: each reaction tube is put into the reactive tank of quantitative fluorescent PCR instrument, mark fluorescent radical species, sample ID and type are set, (this product fluorescent reporter group is FAM, HEX, TAT to the Taqman fluorescence probe of selection, fluorescent quenching group is Eclipse), define sample well, and the amplification program that according to the form below provides carry out pcr amplification:
Table 1 is pcr amplification reaction amplification program
Fluorescent value is read in end of a period in the 3rd step of amplification program；
Data analysis judges:
This saltant type corresponding with this pattern detection site and reference wild-type sample wells of selected institute sample, contrasts three hole pcr amplification curve (CT simultaneouslyARepresent sample aperture CT value, CTWRepresent wild type CT value, CTMRepresent saltant type CT value):
Work as CTM≤CTA< CTWTime, it was shown that there is sudden change in this sample；
Work as CTW=CTATime, it was shown that this sample is wild type。
Fig. 1 is peptide nucleic acid(PNA) mass spectrum described in the embodiment of the present invention；
Fig. 2 be G72D saltant type described in the embodiment of the present invention and in reference wild-type product pcr amplification figure, figure three bars, upper, middle and lower line respectively represent the amplification curve of CK1 the 72nd bit codon mutation type reference material, sample and reference wild-type product；
Fig. 3 be F101L saltant type described in the embodiment of the present invention and in reference wild-type product pcr amplification figure, figure three bars, upper, middle and lower line respectively represent the amplification curve of CK1 the 101st bit codon mutation type reference material, sample and reference wild-type product；
Above example is only used for technical scheme is described; but not be limited; although the present invention being described in detail with reference to previous embodiment; for the person of ordinary skill of the art; still the technical scheme described in previous embodiment can be modified; or wherein portion of techniques feature is carried out equivalent replacement, and these are revised or replace, do not make the essence of appropriate technical solution depart from the spirit and scope of present invention technical scheme required for protection。
Claims (6)
1. the reagent for casein kinase-1CK1 detection in Gene Mutation, it is characterized in that, including the wild type PNA sequence for blocking wild type CK1 gene amplification, for one group of primer pair of specific amplification G72D, F101L saltant type CK1 gene order and saltant type PNA fluorescent probe:
Described detection CK1 gene G72D mutant forward primer such as SEQ ID NO.1；
Described detection CK1 gene G72D sudden change reverse primer such as SEQ ID NO.2；
Described detection CK1 gene F101L mutant forward primer such as SEQ ID NO.3；
Described detection CK1 gene F101L sudden change reverse primer such as SEQ ID NO.4；
Described detection CK1 gene G72D sudden change PNA fluorescent probe such as SEQ ID NO.5；
Described detection CK1 gene F101L sudden change PNA fluorescent probe such as SEQ ID NO.6；
Described specific binding comprise CK1 gene 72 codon wild type PNA sequence such as SEQ ID NO.7；
Described specific binding comprise CK1 gene 101 codon wild type PNA sequence such as SEQ ID NO.8；
The described fluorescent reporter group modifying described 5' end is: FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, and the quenching group modifying described 3' end is: TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL。
2. the reagent for casein kinase-1CK1 detection in Gene Mutation according to claim 1, it is characterized in that, described detectable also includes PCR reactant liquor, 72 codons and 101 codon mutation type reference materials, 72 codons and 101 codon reference wild-type product, and wherein PCR reactant liquor includes: DEPC water, have exo-acting for 5' → 3' archaeal dna polymerase, dNTPs, 10 × PCRBuffer, RNASIN, M-MLV reverse transcriptase, oligo (dT) and the solution containing Mg ion。Described 72 codon mutation type reference materials are the recombinant plasmid dna containing SEQNO.9；Described 72 codon reference wild-type product are the recombinant plasmid dna containing SEQNO.10；Described 101 codon mutation type reference materials are the recombinant plasmid dna containing SEQNO.11；Described 101 codon reference wild-type product are the recombinant plasmid dna containing SEQNO.12。
3. the reagent for casein kinase-1CK1 detection in Gene Mutation according to claim 2, it is characterised in that described in have archaeal dna polymerase exo-acting for 5' → 3' be Taq enzyme。
4. the reagent for casein kinase-1CK1 detection in Gene Mutation according to claim 3, it is characterized in that, final concentration of in pcr amplification reaction system of the described each component of PCR reactant liquor: Taq enzyme 0.01U/ μ l～0.05U/ μ l, dNTPs0.2～0.6mM, 10 × PCRBuffer1 ×, RNASIN40U/ μ l～60U/ μ l, M-MLV reverse transcriptase 200U/ μ l～320U/ μ l, MgCl21.5～5.0mM, solvent is DEPC water；Final concentration of 0.05～0.9 μM of described forward primer, final concentration of 0.05～0.9 μM of described reverse primer, final concentration of 0.05～0.9 μM of described oligo (dT), described complementary final concentration of 0.05～0.9 μM of PNA sequence, final concentration of 0.05～0.9 μM of described fluorescent probe。
5. the reagent for casein kinase-1CK1 detection in Gene Mutation according to claim 1-4, it is characterised in that described reagent carries out the response procedures of real-time fluorescence quantitative PCR and is: 42 DEG C of reverse transcription 20min；94 DEG C of denaturations, 2min；95 DEG C of degeneration, 30s, 58 DEG C, 45s, now collects fluorescence, carries out 40 circulations。
6. the application in the detectable of preparation detection cancerous cell of the reagent described in claim 1-5, described cancerous cell is Testicular Germ Cell cancer, hepatocarcinoma。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610270438.0A CN105695619A (en) | 2016-04-27 | 2016-04-27 | Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610270438.0A CN105695619A (en) | 2016-04-27 | 2016-04-27 | Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105695619A true CN105695619A (en) | 2016-06-22 |
Family
ID=56217765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610270438.0A Pending CN105695619A (en) | 2016-04-27 | 2016-04-27 | Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105695619A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107937604A (en) * | 2016-10-12 | 2018-04-20 | 大韩民国(国立水产科学院) | Detect the genetic marker of infectivity muscle necrosis virus and the method using the genetic marker analyte detection infectivity muscle necrosis virus |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102690877A (en) * | 2011-03-23 | 2012-09-26 | 上海人类基因组研究中心 | Application of CSNK1A1 gene and expression product thereof |
| CN103667492A (en) * | 2013-12-13 | 2014-03-26 | 青岛大学医学院附属医院 | WNT signal channel detecting reagent, PCR (polymerase chain reaction) detection method and application thereof |
-
2016
- 2016-04-27 CN CN201610270438.0A patent/CN105695619A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102690877A (en) * | 2011-03-23 | 2012-09-26 | 上海人类基因组研究中心 | Application of CSNK1A1 gene and expression product thereof |
| CN103667492A (en) * | 2013-12-13 | 2014-03-26 | 青岛大学医学院附属医院 | WNT signal channel detecting reagent, PCR (polymerase chain reaction) detection method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| ERIC S. OKERBERG: "Identification of a Tumor Specific, Active-Site Mutation in Casein Kinase 1 α by Chemical Proteomics", 《PLOS ONE》 * |
| 王昆: "酪蛋白激酶1a与部分肿瘤信号通路", 《中国组织化学与细胞化学杂志》 * |
| 那冬晨: "《环境分子生物学研究技术与方法》", 31 August 2012 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107937604A (en) * | 2016-10-12 | 2018-04-20 | 大韩民国(国立水产科学院) | Detect the genetic marker of infectivity muscle necrosis virus and the method using the genetic marker analyte detection infectivity muscle necrosis virus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104911268B (en) | Detection reagent, PCR detection method and the application of Pygo2 gene mutation in Wnt signal path based on peptide nucleic acid probe | |
| CN107630092B (en) | Application of miR-505-3p in diagnosis, prognosis and treatment of bone metastasis of prostate cancer | |
| CN106995858A (en) | A kind of lncRNA related to liver cancer diagnosis and treatment | |
| CN105821127A (en) | Adenomatous polyposis coli protein APC gene mutation detection reagent and application thereof | |
| CN105838796A (en) | AXIN2 gene mutation detection reagent and application | |
| CN106701900A (en) | Long-chain noncoding RNA HERC2P3 gene and application thereof in gastric cancer | |
| CN101070538A (en) | Human epiterm growth-factor receptor mutation gene and use thereof | |
| CN105950720A (en) | Beta-catenin gene mutation detection reagent in Wnt signal path and applications of beta-catenin gene mutation detection reagent | |
| CN104911271A (en) | Detection reagent based on Pygo2 and FoxM1 gene expression in Wnt signal pathways of peptide nucleic acid probes, PCR detection method and application of detection reagent | |
| CN105039522A (en) | Detection reagent based on FoxM1 gene mutations in Wnt signal paths of peptide nucleic acid probes, PCR detection method and application of detection reagent | |
| CN104911270A (en) | Peptide-nucleic-acid-probe-based detection reagent for Bcl-9 gene mutation in Wnt signal pathway, and PCR (polymerase chain reaction) detection method and application thereof | |
| CN110408703A (en) | Colorectal cancer miRNA marker and its application | |
| CN105713986A (en) | Reagent used for detecting glycogen synthase kinase 3beta (GSK3beta) gene mutation and application | |
| CN103484551B (en) | Kit for detecting EGFR gene hot spot mutation and detection method | |
| CN106244715A (en) | The reagent of a kind of β catenin interaction protein 1 gene abrupt climatic change and application | |
| CN105695619A (en) | Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application | |
| CN107267616A (en) | A kind of application of Noncoding gene biomarker in liver cancer | |
| CN105441405B (en) | BMX spliced body and its application in drug resistance of lung cancer | |
| CN106520776B (en) | A kind of breast cancer kit for screening | |
| CN105713985A (en) | Reagent used for detecting forkhead transcription factor O1 (FOXO1) gene mutation and application | |
| CN110373454A (en) | A kind of kit and method of joint-detection EGFR genetic mutation | |
| CN106636444B (en) | Use of FAM78A gene | |
| CN108192977A (en) | A kind of and relevant molecular marker of gastric cancer occurrence and development | |
| CN110241224B (en) | Use of lncRNA-T065925, kit for diagnosing colorectal cancer and medicament for treating colorectal cancer | |
| CN106367517A (en) | Low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation detection reagents and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |